Known cases of new COVID variant could be the tip of the iceberg: Infectious diseases specialist
The European Union’s standoff with AstraZeneca Plc intensified as Germany urged the bloc to limit vaccine exports, risking tensions with the U.K. and other buyers of the British drugmaker’s COVID shot.
European authorities are under increasing pressure as the bloc’s underwhelming inoculation campaigns threaten to prolong recession-inducing lockdowns. AstraZeneca, which is in the final stages of the EU approval process for its COVID-19 shot, sparked a backlash after saying initial deliveries would be delayed due to production issues.
An export limitation for vaccines produced in the EU would “make sense,” German Health Minister Jens Spahn said Tuesday in an interview on ZDF television. Vaccines leaving the EU “need a license, so we know at least what’s produced in Europe and what leaves Europe, where it goes, and if there’s fair distribution,” he said.
The European Commission, which had called on drugmakers to flag vaccine exports in advance, says that AstraZeneca’s delay would mean significantly fewer deliveries this quarter than previously agreed. The setback follows Pfizer Inc.’s announcement earlier this month that supplies from a factory in Belgium would be reduced for three to four weeks because of work to upgrade capacity.
“Europe invested billions to help develop the world‘s first COVID-19 vaccines,” European Commission President Ursula von der Leyen said in a virtual address to the World Economic Forum. “And now, the companies must deliver. They must honor their obligations.”
The EU, which has had nearly 18 million coronavirus infections, lags well behind the U.K. and the U.S. in vaccinations. Even Denmark, the bloc’s leader, has given only 3.6 shots per 100 people, about one-third the rate in Britain and half of the U.S. pace. Bigger EU countries are further behind, with Germany at 2.1 shots per 100 people.
Britain’s vaccine minister warned the EU against engaging in “vaccine nationalism.” He said the U.K., which left the bloc’s single market and customs union less than a month ago, is confident of hitting a mid-February target to inoculate its most vulnerable citizens despite the row.
“I have every confidence we will get our deliveries as scheduled,” Nadhim Zahawi said Tuesday on LBC Radio, responding to the EU’s proposal, which could disrupt links to Pfizer’s facility in Belgium.
A meeting between the EU and Astra on Monday ended in disagreement. The company offered to boost its EU vaccine deliveries for February, without committing to figures for March. The Commission said it’s not satisfied with the outcome and a new meeting has been scheduled for Wednesday.
Alongside the delivery standoff, AstraZeneca was forced to defend its shot, dismissing a German newspaper report that its vaccine is only effective for 8 per cent of people older than 65.
A report by Handelsblatt late Monday, which cited unidentified sources in Germany’s ruling coalition, is “completely incorrect,” an AstraZeneca spokesman said.
Germany’s health ministry also rejected the report, saying that the newspaper appears to have confused the fact that around 8 per cent of the test subjects were between 56 and 69 years old, and only 3 to 4 per cent were over 70, which isn’t the same as efficacy.
The European Medicines Agency, which started a meeting to review the data on Monday, is expected to decide on whether to approve the vaccine as early as this week. The U.K. has already authorized its use.
A positive recommendation could be issued on Friday “provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete,” the EU’s drugs regulator said.
With a string of bad news delaying a return to normality, EU governments are eager to dodge the blame. Last week, a group of leaders vented at the EMA over what they said is a slow process for approving vaccines, while others have accused the commission of failing to secure sufficient doses early enough on behalf of member states.
Rather than easing restrictions, EU countries are preparing longer and stricter lockdowns. The commission proposed Monday further curbs on travel and a reinforcement of stay-at-home measures.
While the global scramble for vaccines was bound to raise tensions, Spahn raised concerns about the messy process of resolving distribution issues.
“All have to be impacted in a fair and equal way,” Spahn said. “This isn’t about EU first, but Europe’s fair share.”
--With assistance from Jonathan Stearns, Joe Mayes, Suzi Ring and Milda Seputyte.